Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
GRI
GRI Bio, Inc.
GRI Bio, Inc. (GRI) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (C). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Overall Rating
2.8
/ 5.0
C+
Value
B+
Factor Score
3.7
/ 5.0
Growth
C+
Factor Score
2.7
/ 5.0
Profitability
C+
Factor Score
2.6
/ 5.0
Momentum
C
Factor Score
2.2
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-0.9
EV / EBITDA
0.7
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
3.4%
Price Return 12M
-96.2%
Catalyst Signal
0.00
Market Cap
$4.0M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-142.0%
Historical Factor Score Progression
Held C+ for 5 weeks
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | B+ (3.7) | C+ (2.7) | C+ (2.6) | C (2.2) | C+ (2.6) | C+ (2.8) |
| 2026-11-05 | B+ (3.8) | C+ (2.7) | C+ (2.7) | C (2.3) | C+ (2.7) | C+ (2.8) |
| 2026-10-29 | B+ (3.7) | C+ (2.6) | C+ (2.7) | C (2.5) | C+ (2.7) | C+ (2.8) |
| 2026-10-22 | B+ (3.6) | C+ (2.6) | C+ (2.7) | C- (2.1) | C+ (2.6) | C+ (2.7) |
| 2026-10-15 | B+ (3.7) | C+ (2.6) | C+ (2.7) | C- (2.0) | C+ (2.6) | C+ (2.7) |
Page
1
of
4